Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$47 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-6 Mln
ROE
-0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.7
Industry P/E
--
EV/EBITDA
2.6
Div. Yield
0 %
Debt to Equity
0.6
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
60,748,600
CFO
€-293.44 Mln
EBITDA
€-322.41 Mln
Net Profit
€-315.67 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Erytech Pharma S.A. - ADR
| 106.5 | -17.6 | -22.1 | -34.5 | -56.0 | -42.6 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|
|
Erytech Pharma S.A. - ADR
| -86.0 | -74.5 | 25.2 | 8.9 | -69.0 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of... second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-"-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France. Read more
CEO & Director
Mr. Gil Beyen BVBA
CEO & Director
Mr. Gil Beyen BVBA
Headquarters
Lyon
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Erytech Pharma SA - ADR is $0.68 (NASDAQ) as of 26-Jul-2023 09:30 EDT. Erytech Pharma SA - ADR has given a return of -56% in the last 3 years.
Since, TTM earnings of Erytech Pharma SA - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of Erytech Pharma SA - ADR are Rs -- and Rs -- as of 03-Apr-2026.
Erytech Pharma SA - ADR has a market capitalisation of $ 47 Mln as on 26-Jul-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Erytech Pharma SA - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.02
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.